Skip to main content
LTRN
NASDAQ Life Sciences

Lantern Pharma Q3: $7.6M Cash, Going-Concern Doubt, $2M Settlement Accrual

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.372
Mkt Cap
$5.451M
52W Low
$0.362
52W High
$4.34
52W Position info
2.9% above low
Off High info
91% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

LTRN is trading near its 52-week low of $0.362 (2.9% above the low) on light trading volume (0.4× avg).

Summary

Lantern Pharma reported Q3 2026 results with about $7.6 million in cash and explicitly warned it cannot fund operations for the next 12 months without substantial new funding. The quarter's $0.7 million net income came entirely from a non-cash warrant remeasurement gain, while operations lost about $5.4 million including a $2.0 million litigation settlement accrual.


Key Events · Earnings and Guidance · LTRN

  • Going-Concern Warning on $7.6M Cash

    Cash, cash equivalents and marketable securities were approximately $7.6 million at September 30, 2026, down from approximately $10.1 million at December 31, 2025. The company states this is not sufficient to fund operations at the current level for the next 12 months and there is substantial doubt about its ability to continue as a going concern without substantial additional funding.

  • Net Income Is a Non-Cash Warrant Gain

    Net income of approximately $0.7 million ($0.05 per basic share) reflects a roughly $6.0 million non-cash decrease in the fair value of May 2026 offering warrants, driven by the lower stock price. The warrant liability stood at approximately $1.5 million at September 30, 2026; no cash was generated by the remeasurement.

  • Operating Loss $5.4M Including $2M Accrual

    Loss from operations was approximately $5.4 million, or approximately $3.4 million excluding the $2.0 million proposed settlement accrual. R&D fell 36% year over year to approximately $1.6 million, while G&A rose 99% to approximately $3.8 million on the accrual.

  • Settlement Payment Tied to Future Raise

    The proposed $2.0 million settlement with a former part-time consultant pays $1.0 million within 30 days of effectiveness and $1.0 million upon the earlier of raising at least $10.0 million in gross proceeds or the two-year anniversary. It is not yet finalized or effective.


Analysis · LTRN · Life Sciences

Lantern ended September with about $7.6 million in cash and securities and says plainly that this is not enough to fund operations for the next 12 months — a going-concern warning on a company already fighting two Nasdaq deficiencies. The quarter's $0.7 million of net income is an accounting artifact: a roughly $6.0 million non-cash gain from marking down warrant liabilities as the stock fell, not cash earned. The real operating loss was about $5.4 million, including a $2.0 million accrual for a proposed harassment and discrimination settlement whose second $1.0 million payment only comes due if the company raises $10.0 million. With the CEO gone and the CFO running the company on an interim basis, the next capital raise is the event that determines whether the pipeline programs advance.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LTRN was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.36 to $4.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LTRN - Latest Insights

LTRN
Nov 17, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.365
Real-time Price: $0.3724 info
Change: +$0.0074 (+2%) info
Market Cap: $5.451M info
LTRN
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.830
Real-time Price: $0.3724 info
Change: -$0.4576 (-55%) info
Market Cap: $5.451M info
LTRN
Oct 07, 2026, 8:31 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.3724 info
Change: -$0.5776 (-61%) info
Market Cap: $5.451M info
LTRN
Oct 01, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.00
Real-time Price: $0.3724 info
Change: -$0.6276 (-63%) info
Market Cap: $5.451M info
LTRN
Sep 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.01
Real-time Price: $0.3724 info
Change: -$0.6376 (-63%) info
Market Cap: $5.451M info